Leydig cell tumor is a model that resembles human cachexia rather well, because the tumor induced slow progression of anorexia, as well as marked weight loss. The Leydig cell tumors produce TNF and that TNF induces cachexia. Therefore, LPL activator NO-1886 administered to Leydig cell tumor-bearing rats may have beneficial effects. When Leydig cells were inoculated into rats, there was an early decrease in plasma total protein and albumin levels after inoculation, followed by a decrease in plasma glucose and HDL-C, with the animals showing signs of malnutrition throughout. Food consumption decreased after tumor inoculation, and thereafter the rats rapidly grew leaner. LPL activity in rat adipose tissue and adipose tissue weight were decreased by Leydig cell inoculation. NO-1886 prevented the decrease in carcass weight and malnutrition resulting from the appetite suppression attributable to Leydig cell tumors. From these results, the LPL activator is considered to be potentially beneficial for the treatment of cancer cachexia and other wasting syndromes A journal is a periodical publication intended to further progress of science, usually by reporting new research